You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

Details for Patent: 9,668,981


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,668,981 protect, and when does it expire?

Patent 9,668,981 protects DAYTRANA and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 9,668,981
Title:Device for transdermal administration of drugs including acrylic based polymers
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Inventor(s): Kanios; David (Palmetto Bay, FL)
Assignee: NOVEN PHARMACEUTICALS, INC. (Miami, FL)
Application Number:15/091,939
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 9,668,981

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 AB RX Yes No ⤷  Sign Up ⤷  Sign Up METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF ⤷  Sign Up
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 AB RX Yes No ⤷  Sign Up ⤷  Sign Up METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF ⤷  Sign Up
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 AB RX Yes No ⤷  Sign Up ⤷  Sign Up METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF ⤷  Sign Up
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,668,981

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2006041911 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.